Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

W. V. van Riel · SciRah

Researcher profile · Semantic Scholar

W. V. van Riel

Share profile

W. V. van Riel — researcher profile on SciRah

h-index: 9
Works: 20
Citations: 715

Most-cited papers

CFEOM1-associated kinesin KIF21A is a cortical microtubule growth inhibitor.
B. van der Vaart, W. V. van Riel, Harinath Doodhi, J. Kevenaar +17 more
2013Developmental Cell179 citations Open access
Semantic Scholar
MAP7 family proteins regulate kinesin-1 recruitment and activation
Peter Jan Hooikaas, Maud Martin, Tobias Mühlethaler, Gert-Jan Kuijntjes +13 more
2018bioRxiv146 citations Open access
Semantic Scholar
Tumor type-dependent function of the par3 polarity protein in skin tumorigenesis.
Sandra Iden, W. V. van Riel, Ronny Schäfer, Ji-Ying Song +3 more
2012Cancer Cell118 citations Open access
Semantic Scholar
Multivalent glycopeptide dendrimers for the targeted delivery of antigens to dendritic cells.
J. Garcia-Vallejo, M. Ambrosini, A. Overbeek, W. V. van Riel +7 more
2013Molecular Immunology107 citations
Semantic Scholar
Kinesin-4 KIF21B is a potent microtubule pausing factor
W. V. van Riel, Ankit Rai, Sarah Bianchi, E. Katrukha +6 more
2017eLife58 citations Open access
Semantic Scholar
Kinesin-4 KIF21B limits microtubule growth to allow rapid centrosome polarization in T cells
Peter Jan Hooikaas, Hugo G. J. Damstra, Oane Gros, W. V. van Riel +6 more
2020bioRxiv41 citations Open access
Semantic Scholar
Structural basis for misregulation of kinesin KIF21A autoinhibition by CFEOM1 disease mutations
Sarah Bianchi, W. V. van Riel, S. Kraatz, N. Olieric +10 more
2016Scientific Reports28 citations Open access
Semantic Scholar
Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020
J. Kooijman, W. V. van Riel, J. Dylus, M. Prinsen +10 more
2022Frontiers in Oncology21 citations Open access
Semantic Scholar
Chemotherapy sensitivity testing on ovarian cancer cells isolated from malignant ascites
Judith E. den Ouden, G. Zaman, J. Dylus, A. V. van Doornmalen +6 more
2020OncoTarget13 citations Open access
Semantic Scholar
MAP7 family proteins are microtubule-tethered allosteric activators of kinesin-1
Peter Jan Hooikaas, Maud Martin, Gert-Jan Kuijntjes, Cathelijn A. E. Peeters +11 more
20183 citations
Semantic Scholar
Abstract 5645: BAL0891: A novel dual TTK/PLK1 mitotic checkpoint inhibitor (MCI) that drives aberrant tumor cell division resulting in potent anti-cancer activity
H. Lane, F. Bachmann, E. Zanini, P. Mcsheehy +9 more
2022Cancer Research2 citations
Semantic Scholar
Abstract A100: Large-scale cell line profiling of small molecule MAPK pathway inhibitors identifies important differences between therapeutics acting on the same biochemical target
J. Kooijman, Awan Al Koerdi, W. V. van Riel, E. van den Bossche +4 more
2023Molecular Cancer Therapeutics0 citations
Semantic Scholar
Abstract B061: Sensitivity and resistance mechanisms of human cancer cell lines treated with PARP, POLθ, and ATR inhibitor combinations in 2D and 3D spheroid cell viability assays
Janneke J. Melis, J. Kooijman, S. Wetemans, Suzan Geerdink-Datema +4 more
2023Molecular Cancer Therapeutics0 citations
Semantic Scholar
30P Comparative biochemical and cellular profiling of kinase inhibitors approved for clinical use from 2018 to 2020
J. Kooijman, W. V. van Riel, M. Prinsen, J. Dylus +8 more
2022Annals of Oncology0 citations Open access
Semantic Scholar
42P BAL0891: A novel, small molecule, dual TTK/PLK1 mitotic checkpoint inhibitor (MCI) with potent single agent activity
H. Lane, E. Zanini, N. Forster-Gross, K. Litherland +13 more
2022Annals of Oncology0 citations Open access
Semantic Scholar
Abstract 1080: Altered response to BET-bromodomain inhibitors JQ1 and I-BET-762 targeting c-Myc in erdafitinib-resistant endometrial carcinoma cell line AN3 CA
W. V. van Riel, Janneke J. Melis, Demi H. J. Vogels, W. Mulder +3 more
2021Experimental and Molecular Therapeutics0 citations
Semantic Scholar
Abstract 1480: Comparative cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020
J. Kooijman, W. V. van Riel, M. Prinsen, J. Dylus +10 more
2021Experimental and Molecular Therapeutics0 citations
Semantic Scholar
Author response: Kinesin-4 KIF21B limits microtubule growth to allow rapid centrosome polarization in T cells
Peter Jan Hooikaas, Hugo G. J. Damstra, Oane Gros, W. V. van Riel +6 more
20200 citations Open access
Semantic Scholar
Abstract 5604: High TDO and IDO1 expression in ovarian cancer-associated cells isolated from malignant ascites
W. V. van Riel, A. V. van Doornmalen, W. Mulder, D. Vu +5 more
2020Immunology0 citations
Semantic Scholar
Shaping the tracks : Regulation of microtubule dynamics by kinesins KIF21A and KIF21B
W. V. van Riel
20160 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Akhmanova×7
Invite
A. Akhmanova — researcher profile on SciRah
J. Dylus×7
Invite
J. Dylus — researcher profile on SciRah
J. Kooijman×6
Invite
J. Kooijman — researcher profile on SciRah
L. Kapitein×5
Invite
L. Kapitein — researcher profile on SciRah

×5

Invite

J. D. de Roos — researcher profile on SciRah

Invite

G. Zaman — researcher profile on SciRah

Invite

R. Buijsman — researcher profile on SciRah

Invite

E. Katrukha — researcher profile on SciRah

C. Hoogenraad×4

Invite

C. Hoogenraad — researcher profile on SciRah

Peter Jan Hooikaas×4

Invite

Peter Jan Hooikaas — researcher profile on SciRah

Invite

Maud Martin — researcher profile on SciRah

Invite

Y. Grobben — researcher profile on SciRah